HitGen Change in Working Capital

What does HitGen do? HitGen Inc. generates revenue through DEL screening services, DEL library customization, chemical synthesis, and transfer of new drug R&D projects. The company serves pharmaceutical and biotechnology firms seeking to develop seed and lead compounds for drug discovery. Its domestic market focus includes clients in China, while international clients also access its DEL technology solutions. HitGen's services support the research and development phase of drug development, targeting companies in the pharmaceutical sector that require advanced compound libraries for early-stage drug discovery. The firm's DEL technology enables the creation of large compound libraries for high-throughput screening, which is critical for identifying potential drug candidates. HitGen's services are tailored to clients' needs, offering customized DEL libraries and synthesis support for drug development projects. Its business model relies on providing specialized R&D services to pharmaceutical companies that require efficient compound screening and lead optimization. HitGen's offerings include the research and creation of DEL technology, development of hit and lead compounds, and transfer of new drug R&D projects. The company's DEL screening services are a core product, allowing clients to identify promising compounds quickly. By focusing on DEL technology, HitGen positions itself as a key provider of specialized services for drug discovery in both domestic and international markets. HitGen is one of the most popular companies on Eulerpool.